Inhibikase Therapeutics (IKT) SC 13G Inhibikase Therapeutics / SP IKT ownership change

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that they are filing this statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13G with respect to the Common Stock of Inhibikase Therapeutics, Inc. beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13G.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of October 28, 2024.

SP SOLEUS HOLDINGS LLC
By:	/s/ Chris Timchak
	Name: Chris Timchak
	Title: Vice President
SP IKT HOLDINGS LLC
By:	/s/ Chris Timchak
	Name: Chris Timchak
	Title: Vice President